We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VNO:NYSEVornado Realty Trust Analysis

Data as of 2026-05-09 - not real-time

$32.16

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Vornado Realty Trust (VNO) is trading at $32.16, well below its DCF-derived fair value of $42.69, implying a potential upside of roughly 30% while its trailing P/E of 8.81 is dramatically lower than the industry average of 32.57, positioning the stock as a clear value play. The recent quarter showed a modest revenue dip of 0.5% YoY to $459.1 M but a healthy EPS increase to $0.52, beating the consensus estimate and delivering a 21% year‑over‑year earnings lift, supported by a robust operating cash flow of $1.25 B and free cash flow of $1.21 B. Technicals are mixed: the 20‑day SMA ($29.65) sits below the price, the MACD line remains bullish over its signal, yet the RSI at 71 signals the stock is overbought and may face short‑term pressure near the $32.56 resistance level.
The balance sheet carries a high leverage profile (debt‑to‑equity ≈ 126%) but is cushioned by $1.11 B of cash and a low dividend payout ratio of 20%, sustaining a 2.31% yield that appears dividend‑sustainable. Recent strategic activity, notably the acquisition of a 49% stake in Park Avenue Plaza at a $1.1 B valuation—significantly below replacement cost—adds a compelling growth catalyst in a sector that has underperformed.
Overall, VNO offers a compelling blend of undervalued pricing, solid cash generation, and dividend appeal, but investors must weigh heightened sector headwinds for office REITs, elevated beta (≈1.2), and a 30‑day volatility of over 31% when sizing position size and horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI indicates overbought conditions
  • Price approaching technical resistance
  • Increasing volume supports potential bounce

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Significant valuation gap to DCF fair value
  • Strategic acquisition at a deep discount
  • Sustainable dividend yield with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong cash flow generation and balance‑sheet liquidity
  • Undervalued relative to peers and fair‑value estimate
  • Long‑term growth upside from premium asset purchases

Key Metrics & Analysis

Financial Health

Revenue Growth-2.20%
Profit Margin42.89%
P/E Ratio8.8
ROE12.60%
ROA1.14%
Debt/Equity126.13
P/B Ratio1.3
Op. Cash Flow$1.3B
Free Cash Flow$1.2B
Industry P/E32.6

Technical Analysis

TrendNeutral
RSI71.3
Support$26.77
Resistance$32.56
MA 20$29.65
MA 50$27.68
MA 200$34.00
MACDBullish
VolumeIncreasing
Fear & Greed Index90.73

Valuation

Fair Value$42.69
Target Price$32.46
Upside/Downside0.94%
GradeUndervalued
TypeValue
Dividend Yield2.31%

Risk Assessment

Beta1.23
Volatility31.22%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.